Contract Manufacturing Industry News

51. Vetter Prepares For Further Growth 4/26/2012

    As part of its business growth strategy, Vetter, a leading contract development and manufacturing organization (CDMO), has announced that a triple-digit million euro syndicated loan has been arranged with a consortium of renowned banks led by Deutsche Bank AG, the Landesbank Baden-Württemberg, and Commerzbank AG at the end of march. 

52. Dalton Announces Collaboration Developing A Promising Broad Spectrum Antiviral Agent 4/25/2012

    Dalton Pharma Services today announced a manufacturing agreement for a potent antiviral agent developed by Defense Research and Development Canada (DRDC), an agency of the Department of National Defense.

53. Quintiles Names Tom Pike CEO 4/25/2012

    Quintiles, the world’s leading global biopharmaceutical services company, today announced the appointment of Tom Pike as chief executive officer.

54. Strength Of Aptalis Pharmaceutical Technologies Patents Confirmed By AMRIX® Verdict 4/25/2012

    Aptalis Pharmatech, Inc. (previously known as Eurand, Inc.) and Cephalon, Inc. a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd, and Anesta AG prevailed in their appeal to  the U.S. Court of Appeals for the Federal Circuit which reversed a lower court’s determination and held that two patents covering the AMRIX^® muscle relaxant (Cyclobenzaprine Hydrochloride Extended-Release Capsules) are valid.  

55. Cetero Reaches Final Resolution With The Food And Drug Administration 4/24/2012

    Leading early-phase Contract Research Organization (CRO) Cetero Research recently announced it has reached a final resolution! with the U.S. Food and Drug Administration (FDA) over studies the company conducted in its Houston bioanalytical laboratory between April 1, 2005 through June 15, 2010.

56. Therapure Announces Opening Of Custom Biologics Manufacturing Wing 4/20/2012

    Recently marked the official opening of Therapure Biopharma Inc.’s Custom Biologics Manufacturing Wing, which supports the development and manufacture of innovative medical treatments.

57. AMRI Announces Development And Manufacturing Deal With Biota Holdings Limited 4/17/2012

    AMRI , a leading global contract research and manufacturing organization, was selected by Biota Holdings Limited , a leading anti-infective drug development company based in Australia, to further develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. AMRI will provide these services to support a New Drug Application for laninamivir to the United States Food and Drug Administration (FDA).

58. Nimble Approach To Partnerships Will Generate Value For Both CROs And The Pharmaceutical Industry, According To New Study 4/11/2012
    As more and more R&D is outsourced by pharmaceutical companies, a study released today provides new insight into how to structure the relevant partnerships for success.
59. BASF And Catalent Join Forces To Solve Bioavailability Challenges 4/9/2012
    Catalent Pharma Solutions and BASF have entered into a broad collaboration and Open Alliance to provide solutions to overcome bioavailability challenges of new molecular entities with solubility or permeability challenges.
60. Almac And Affymetrix Announce A Global Distribution Agreement For Almac's Xcel Array 4/2/2012
    Almac recently announced that it has signed an exclusive global distribution deal with Affymetrix, Inc. enabling them to directly sell Almac’s proprietary Xcel array for biomarker discovery, development and delivery worldwide.